Marktanalyse - Pertussis (Whooping Cough) - Pipeline Review, H2 2016

Global Markets Direct
12.2016
111 Seiten

 
Typ:
Marktanalyse
Verfüg­barkeit:
verfügbar
Regionen/­Länder:
  • Europa
  • Asien / Pazifik
  • Mittlerer Osten / Afrika
  • Nordamerika / USA
  • Australien
  • Mittel- / Südamerika
Sprache:
Englisch

Bitte wählen Sie ein Lieferformat und klicken Sie unten auf einen Bestellbutton:

PDF-Datei per E-Mail, Single User Price, versandkostenfrei
PDF-Datei per E-Mail, Site License Price**, versandkostenfrei
PDF-Datei per E-Mail, Enterprisewide Price (Global Site License)***, versandkostenfrei


Hinweise: **The report can be shared by users within one office (one geographical location) ***Across Geographical locations (by the purchasing company only)

Pertussis (Whooping Cough) - Pipeline Review, H2 2016


Summary


Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pertussis (Whooping Cough) — Pipeline Review, H2 2016, provides an overview of the Pertussis (Whooping Cough) (Infectious Disease) pipeline landscape.

Pertussis, also known as whooping cough, is a highly contagious respiratory disease. It is caused by the bacterium Bordetella pertussis. Symptoms include runny nose, nasal congestion, sneezing, red, watery eyes and dry cough. Treatment includes antibiotics.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Pertussis (Whooping Cough) — Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Pertussis (Whooping Cough) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pertussis (Whooping Cough) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Pertussis (Whooping Cough) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 1, 12, 3, 5, 1, 9 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 1 and 3 molecules, respectively.

Pertussis (Whooping Cough) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.


Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Pertussis (Whooping Cough) (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Pertussis (Whooping Cough) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Pertussis (Whooping Cough) (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Pertussis (Whooping Cough) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Pertussis (Whooping Cough) (Infectious Disease)


Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Pertussis (Whooping Cough) (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Pertussis (Whooping Cough) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Pertussis (Whooping Cough) Overview 8

Therapeutics Development 9

Pipeline Products for Pertussis (Whooping Cough) - Overview 9

Pipeline Products for Pertussis (Whooping Cough) - Comparative Analysis 10

Pertussis (Whooping Cough) - Therapeutics under Development by Companies 11

Pertussis (Whooping Cough) - Therapeutics under Investigation by Universities/Institutes 13

Pertussis (Whooping Cough) - Pipeline Products Glance 14

Late Stage Products 14

Clinical Stage Products 15

Early Stage Products 16

Pertussis (Whooping Cough) - Products under Development by Companies 17

Pertussis (Whooping Cough) - Products under Investigation by Universities/Institutes 19

Pertussis (Whooping Cough) - Companies Involved in Therapeutics Development 20

Beijing Minhai Biotechnology Co Ltd 20

Beijing Tiantan Biological Products Co Ltd 21

Bharat Biotech International Ltd 22

Biken Inc 23

Biological E Ltd 24

Boryung Pharmaceutical Co Ltd 25

Daiichi Sankyo Company Ltd 26

DBV Technologies SA 27

GlaxoSmithKline Plc 28

Green Cross Corp 29

ILiAD Biotechnologies LLC 30

Indian Immunologicals Ltd 31

Kaketsuken KK 32

LG Life Science LTD 33

NanoBio Corp 34

Panacea Biotec Ltd 35

Sanofi Pasteur SA 36

Serum Institute of India Ltd 37

Shantha Biotechnics Ltd 38

Synthetic Biologics Inc 39

Zydus Cadila Healthcare Ltd 40

Pertussis (Whooping Cough) - Therapeutics Assessment 41

Assessment by Monotherapy Products 41

Assessment by Combination Products 42

Assessment by Target 43

Assessment by Route of Administration 45

Assessment by Molecule Type 47

Drug Profiles 49

(diphtheria + Haemophilus influenza [serotype B] + hepatitis B + pertussis (wholl cell) + tetanus) (pentavalent) vaccine - Drug Profile 49

(diphtheria + Haemophilus influenza [serotype B] + pertussis (acellular) + polio + tetanus) vaccine - Drug Profile 50

(diphtheria + haemophilus influenza [serotype B] + pertussis (acellular) + tetanus) vaccine - Drug Profile 51

(diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + meningococcal [serotype C] + pertussis (whole cell) + poliomyelitis + tetanus) (7-valent) vaccine - Drug Profile 52

(diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + polio + tetanus) (hexavalent) vaccine - Drug Profile 53

(diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + poliomyelitis + tetanus) (hexavalent) vaccine - Drug Profile 54

(diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + poliomyelitis + tetanus) (hexavalent) vaccine - Drug Profile 55

(diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + tetanus) (pentavalent) vaccine - Drug Profile 56

(diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + tetanus) (pentavalent) vaccine - Drug Profile 57

(diphtheria + Haemophilus influenzae [serotype B] + pertussis (whole cell) + polio + tetanus)(pentavalent) vaccine - Drug Profile 58

(diphtheria + Haemophilus influenzae [serotype B] + pertussis (whole-cell) + tetanus) vaccine - Drug Profile 59

(diphtheria + haemophilus influenzae [serotype B] + pertussis + poliomyelitis + tetanus) vaccine - Drug Profile 60

(diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile 61

(diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile 62

(diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile 63

(diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile 64

(diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile 65

(diphtheria + pertussis (acellular) + tetanus) vaccine 1 - Drug Profile 66

(diphtheria + pertussis (acellular) + tetanus) vaccine 2 - Drug Profile 67

(diphtheria + pertussis (whole cell) + tetanus) vaccine - Drug Profile 68

(diphtheria + pertussis (whole-cell) + tetanus) vaccine - Drug Profile 69

(diphtheria + tetanus + pertussis (acellular) + hepatitis B + poliomyelitis [serotypes Mahoney + MEF-1 + Saukett] + haemophilus influenza [serotype B]) vaccine - Drug Profile 70

(diphtheria + tetanus + pertussis (acellular) + poliomyelitis + haemophilus influenzae [serotype B]) vaccine - Drug Profile 72

(hepatitis B + pertussis) vaccine - Drug Profile 73

bladder cancer + pertussis + tuberculosis vaccine - Drug Profile 74

BVN-002 - Drug Profile 75

Eupenta - Drug Profile 76

GC-3111A - Drug Profile 77

KD-370 - Drug Profile 78

LBVD - Drug Profile 79

pertussis (acellular) vaccine - Drug Profile 80

pertussis (acellular) vaccine - Drug Profile 81

pertussis (whole cell) vaccine - Drug Profile 82

pertussis [strain BPZE1] vaccine - Drug Profile 83

pertussis vaccine - Drug Profile 85

pertussis vaccine - Drug Profile 86

pertussis vaccine - Drug Profile 87

SYN-005 - Drug Profile 89

VN-0103 - Drug Profile 91

VN-0105 - Drug Profile 92

Pertussis (Whooping Cough) - Dormant Projects 93

Pertussis (Whooping Cough) - Discontinued Products 95

Pertussis (Whooping Cough) - Product Development Milestones 96

Featured News & Press Releases 96

Appendix 107

Methodology 107

Coverage 107

Secondary Research 107

Primary Research 107

Expert Panel Validation 107

Contact Us 107

Disclaimer 108





List of Tables

Number of Products under Development for Pertussis (Whooping Cough), H2 2016 12

Number of Products under Development for Pertussis (Whooping Cough) - Comparative Analysis, H2 2016 13

Number of Products under Development by Companies, H2 2016 15

Number of Products under Investigation by Universities/Institutes, H2 2016 16

Comparative Analysis by Late Stage Development, H2 2016 17

Comparative Analysis by Clinical Stage Development, H2 2016 18

Comparative Analysis by Early Stage Development, H2 2016 19

Products under Development by Companies, H2 2016 20

Products under Development by Companies, H2 2016 (Contd..1) 21

Products under Investigation by Universities/Institutes, H2 2016 22

Pertussis (Whooping Cough) - Pipeline by Beijing Minhai Biotechnology Co Ltd, H2 2016 23

Pertussis (Whooping Cough) - Pipeline by Beijing Tiantan Biological Products Co Ltd, H2 2016 24

Pertussis (Whooping Cough) - Pipeline by Bharat Biotech International Ltd, H2 2016 25

Pertussis (Whooping Cough) - Pipeline by Biken Inc, H2 2016 26

Pertussis (Whooping Cough) - Pipeline by Biological E Ltd, H2 2016 27

Pertussis (Whooping Cough) - Pipeline by Boryung Pharmaceutical Co Ltd, H2 2016 28

Pertussis (Whooping Cough) - Pipeline by Daiichi Sankyo Company Ltd, H2 2016 29

Pertussis (Whooping Cough) - Pipeline by DBV Technologies SA, H2 2016 30

Pertussis (Whooping Cough) - Pipeline by GlaxoSmithKline Plc, H2 2016 31

Pertussis (Whooping Cough) - Pipeline by Green Cross Corp, H2 2016 32

Pertussis (Whooping Cough) - Pipeline by ILiAD Biotechnologies LLC, H2 2016 33

Pertussis (Whooping Cough) - Pipeline by Indian Immunologicals Ltd, H2 2016 34

Pertussis (Whooping Cough) - Pipeline by Kaketsuken KK, H2 2016 35

Pertussis (Whooping Cough) - Pipeline by LG Life Science LTD, H2 2016 36

Pertussis (Whooping Cough) - Pipeline by NanoBio Corp, H2 2016 37

Pertussis (Whooping Cough) - Pipeline by Panacea Biotec Ltd, H2 2016 38

Pertussis (Whooping Cough) - Pipeline by Sanofi Pasteur SA, H2 2016 39

Pertussis (Whooping Cough) - Pipeline by Serum Institute of India Ltd, H2 2016 40

Pertussis (Whooping Cough) - Pipeline by Shantha Biotechnics Ltd, H2 2016 41

Pertussis (Whooping Cough) - Pipeline by Synthetic Biologics Inc, H2 2016 42

Pertussis (Whooping Cough) - Pipeline by Zydus Cadila Healthcare Ltd, H2 2016 43

Assessment by Monotherapy Products, H2 2016 44

Assessment by Combination Products, H2 2016 45

Number of Products by Stage and Target, H2 2016 47

Number of Products by Stage and Route of Administration, H2 2016 49

Number of Products by Stage and Molecule Type, H2 2016 51

Pertussis (Whooping Cough) - Dormant Projects, H2 2016 96

Pertussis (Whooping Cough) - Dormant Projects (Contd..1), H2 2016 97

Pertussis (Whooping Cough) - Discontinued Products, H2 2016 98





List of Figures

Number of Products under Development for Pertussis (Whooping Cough), H2 2016 12

Number of Products under Development for Pertussis (Whooping Cough) - Comparative Analysis, H2 2016 13

Number of Products under Development by Companies, H2 2016 14

Number of Products under Investigation by Universities/Institutes, H2 2016 16

Comparative Analysis by Late Stage Development, H2 2016 17

Comparative Analysis by Clinical Stage Development, H2 2016 18

Comparative Analysis by Early Stage Products, H2 2016 19

Assessment by Monotherapy Products, H2 2016 44

Assessment by Combination Products, H2 2016 45

Number of Products by Targets, H2 2016 46

Number of Products by Stage and Targets, H2 2016 46

Number of Products by Routes of Administration, H2 2016 48

Number of Products by Stage and Routes of Administration, H2 2016 48

Number of Products by Molecule Types, H2 2016 50

Number of Products by Stage and Molecule Types, H2 2016 50

* Alle Preise sind netto ausgewiesen. In Abhängigkeit von Ihrer Rechnungsanschrift ist hierauf noch USt. zu entrichten (Deutschland z.Z. 19%). Unser Angebot richtet sich ausschließlich an Unternehmen, Gewerbetreibende und Freiberufler.

 

Über marktforschung.de

Branchenwissen an zentraler Stelle bündeln und abrufbar machen – das ist das Hauptanliegen von marktforschung.de. Unser breites Informationsangebot rund um die Marktforschung richtet sich sowohl an Marktforschungsinstitute, Felddienstleister, Panelbetreiber und Herausgeber von Studien, Marktdaten sowie Marktanalysen als auch an deren Kunden aus Industrie, Handel und Dienstleistungsgewerbe.

facebook twitter google plus